文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

HypoFocal II期试验主要终点:PSMA-PET与MRI引导的前列腺癌局灶增量放疗的安全性与生活质量

Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01).
PubMed 文献 · Radiother Oncol · 2025-04-15

HypoFocal II期试验纳入中高危前列腺癌患者,A组接受20次60 Gy中度大分割放疗联合局灶增量至75 Gy,B组接受全腺体15 Gy高剂量率近距离放疗联合增量至19 Gy后行20次44 Gy外照射。两年随访时A组2级及以上泌尿和胃肠毒性分别为24%和8%,B组为10%和0%;A组报告2例3级胃肠毒性。结论认为基于mpMRI和PSMA-PET的局灶增量安全可行,HDR-BT方案毒性和生活质量良好。

要点

  • A组2级及以上泌尿毒性24%、胃肠毒性8%,B组分别为10%和0%。
  • A组报告2例3级胃肠毒性,归因于多因素起源和干预措施。
  • 生活质量总体良好,A组肠道症状和B组性功能出现显著且最小重要差异。

核心结论

  • 这是首个证明基于mpMRI和PSMA-PET的局灶增量在中度大分割放疗及HDR-BT联合外照射中安全可行的试验。
  • HDR-BT方案尤其提供良好的毒性和生活质量特征。
  • 放射性直肠炎需要仔细管理。

研究设计与样本

  • HypoFocal为双中心II期试验,报告中位两年随访的主要终点、毒性和生活质量结果。
  • A组接受20次60 Gy中度大分割放疗联合局灶增量至75 Gy。
  • B组接受全腺体15 Gy高剂量率近距离放疗联合增量至19 Gy,随后行20次44 Gy外照射。
  • 增量基于mpMRI和PSMA-PET联合信息。
  • A组25例、B组30例中高危前列腺癌患者接受治疗。

主要发现

  • 两年随访时A组2级及以上泌尿毒性为24%、胃肠毒性为8%。
  • 两年随访时B组2级及以上泌尿毒性为10%、胃肠毒性为0%。
  • A组报告2例3级胃肠毒性,可归因于多因素起源和干预措施。
  • 生活质量良好,仅A组肠道症状和B组性功能出现显著且最小重要差异。
  • 每组各有1例患者复发。

关键数值与推荐

  • 泌尿和胃肠毒性按CTCAEv5.0评估。
  • 生活质量采用经验证的问卷IPSS、QLQ-PR25和QLQ-PR30评估。

临床怎么用

  • 基于mpMRI和PSMA-PET的局灶增量在中度大分割放疗和HDR-BT联合外照射中安全可行。
  • HDR-BT方案提供良好的毒性和生活质量特征。
  • 放射性直肠炎需要仔细管理。

局限性

  • 局限性为样本量相对较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To present the primary endpoint results, toxicities and quality of life (QoL) after two-year follow-up (FU) of the HypoFocal Phase II trial. MATERIAL AND METHODS: Intermediate- and high-risk prostate cancer (PCa) patients were treated with moderately hypofractionated radiotherapy (MHRT) of 60 Gy in 20 fractions and a focal-boost of up to 75 Gy in Arm A, or high-dose-rate-brachytherapy (HDR-BT) of 15 Gy to the whole-gland with a boost of up to 19 Gy, followed by external beam RT (EBRT) of 44 Gy in 20 fractions in Arm B. Boost was based on combined information by multiparametric-magentic-resonance-tomography (mpMRI) and positron-emission-tomography targeting prostate-specific-membrane-antigen (PSMA-PET). Genitourinary (GU) and gastrointestinal (GI) toxicities were assessed according to CTCAEv5.0. QoL was assessed with validated questionnaires (IPSS, QLQ-PR25 and QLQ-PR30). RESULTS: Twenty-five patients were treated with MHRT and 30 patients with HDR-BT + EBRT. At two-year-FU, the rate of grade 2 + GU and GI toxicity was 24 % and 8 % in Arm A and 10 % and 0 % in Arm B, respectively. Two grade 3 GI toxicities were reported in Arm A, which can be attributed to multifactorial genesis and interventions. QoL was good with significant and minimally-important-differences only in bowel symptoms in Arm A and sexual functioning in Arm B. One patient in each arm relapsed. Limitations are the relatively small sample size. CONCLUSION: This is the first trial do demonstrate safety and feasibility of focal dose-escalation based on mpMRI and PSMA-PET in MHRT and HDR-BT + EBRT in intermediate- and high-risk PCa. Particularly, HDR-BT offers good toxicity and QoL profiles. Radiation proctitis demands careful management.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Spohn SKB, Zamboglou C, Bürkle SL, et al. Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01). Radiother Oncol. 2025. PMID: 40246173. doi:10.1016/j.radonc.2025.110883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。